Enact Holdings (NASDAQ:ACT) Azioni

Enact Holdings

Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.

Actavis

Enact Holdings Inc

Achain

Acacia Research Corporation - Common Stock

Acacia Research Corp

Aduro Clean Technologies Inc Ordinary Shares

ARTEC GLOBAL MEDIA INC by Artec Global Media, Inc.

Artec Global Media Inc

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics Inc

LeaderShares Activist Leaders ETF

ADVANCED CONTAINER by Advanced Container Technologies Inc.

Advanced Container Technologies Inc

UBS analyst Douglas Harter maintains Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) with a Neutral and raises the price target from $38 to $40.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on Enact Holdings, Raises Price Target to $40

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Bose George downgraded the rating for Enact Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) from Outperform to Market Perform and maintained the price target of $39. Enact Holdings shares closed at $37.32 on Friday. <a href="https://www.benzinga.com/quote/ACT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert downgraded Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) from Buy to Hold. Plus Therapeutics shares closed at $0.6479 on Friday. <a href="https://www.benzinga.com/quote/PSTV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sheila Kahyaoglu downgraded the rating for Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Buy to Hold and cut the price target from $75 to $65. Parsons shares closed at $62.81 on Friday. <a href="https://www.benzinga.com/quote/PSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Matthew Prisco downgraded Onto Innovation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) from Overweight to Neutral and lowered the price target from $250 to $135. Onto Innovation shares closed at $127.10 on Friday. <a href="https://www.benzinga.com/quote/ONTI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Paul Golding downgraded the rating for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from Outperform to Neutral and lowered the price target from $110 to $50. Block shares closed at $46.53 on Friday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying XYZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-1024x590.png" alt="" class="wp-image-901156" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

ONTO

PSTV

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Keefe, Bruyette &amp; Woods analyst Bose George downgrades Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) from Outperform to Market Perform and maintains the price target from $39 to $39.

Keefe, Bruyette & Woods Downgrades Enact Holdings to Market Perform, Maintains Price Target to $39

Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.08 by 1.85 percent. This is a 5.77 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $306.78 million which beat the analyst consensus estimate of $302.24 million by 1.50 percent. This is a 5.21 percent increase over sales of $291.58 million the same period last year.

Earnings

Earnings Beats

Enact Holdings Q1 Adj. EPS $1.10 Beats $1.08 Estimate, Sales $306.78M Beat $302.24M Estimate

Enact Holdings, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) announced that its Board of Directors declared a quarterly dividend of $0.21 per common share, an increase of 14% from the prior quarter's dividend. This dividend will be payable on June 11, 2025, to shareholders of record on May 19, 2025.
Additionally, Enact's Board of Directors authorized a new share repurchase program under which the company may purchase up to $350 million of its common stock. The new share repurchase authorization is in addition to the company's current $250 million share repurchase program, of which $6 million remains as of April 25, 2025.

Dividends

Buybacks

Enact Holdings Hikes Quarterly Dividend By 14% From $0.18 To $0.21 Per Share; Board Authorizes $350M Share Repurchase Program

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

U.S. stocks were lower, with the Dow Jones index dipping over 800 points on Thursday.
Shares of PriceSmart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) rose sharply during Thursday's session following better-than-expected <a href="https://www.benzinga.com/quote/PSMT">second-quarter earnings.</a>
Pricesmart reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate of $1.40 per share. The company reported quarterly sales of $1.363 compared to the analyst consensus estimate of $1.359 billion.
PriceSmart shares jumped 7.2% to $91.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) shares jumped 17.7% to $12.16. The company announced that its board has initiated a formal review process to evaluate strategic alternatives to maximize shareholder value.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) gained 10% to $21.40.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) rose 9% to $19.84.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) jumped 8.6% to $8.00.</li>
<li>Enact Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) gained 8% to $36.04 after the company announced it is set to join the S&amp;P SmallCap 600 on April 16.</li>
<li>SBC Medical Group Holdings Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NASDAQ">SBC</a>) rose 6.6% to $3.3800.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) rose 6.7% to $71.33 after the company received FDA clearance for its G7 15-day continuous glucose monitoring system.</li>
<li>ATRenew Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NYSE">RERE</a>) gained 5% to $2.3350.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) shares rose 4.6% to $22.54.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) gained 4.4% to $15.32.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44730791/top-3-health-care-stocks-that-could-lead-to-your-biggest-gains-in-q2">Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

DXCM

KROS

PSMT

RERE

SMMT

USAR

PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday

WIIM

Enact Holdings shares are trading higher after the company announced it's set to join the S&P SmallCap 600 on April 16.

General

Enact Holdings To Replace SolarWinds Corp. In The S&P SmallCap 600, Effective April 16,2025

Keefe, Bruyette &amp; Woods analyst Bose George maintains Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) with a Outperform and lowers the price target from $41 to $39.

Keefe, Bruyette & Woods Maintains Outperform on Enact Holdings, Lowers Price Target to $39

Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) just disclosed its Q4 earnings on Tuesday, February 4, 2025 at 04:15 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Enact Holdings beat estimated earnings by 6.0%, reporting an EPS of $1.09 versus an estimate of $1.03.
Revenue was up $5.59 million from the same period last year.
<h3>Previous Earnings Records</h3>
During the previous quarter, the company beat on EPS by $0.15, leading to a 2.0% drop share price change the next day.
Here's a look at Enact Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.01</td>
<td>0.98</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.27</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>309.26M</td>
<td>298.83M</td>
<td>294.12M</td>
<td>299.81M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>309.59M</td>
<td>298.83M</td>
<td>291.58M</td>
<td>296.19M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enact Holdings <a href="https://www.benzinga.com/quote/ACT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: Enact Holdings Q4

The Q4 earnings report for Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) was released on Tuesday, February 4, 2025 at 04:15 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Enact Holdings beat estimated earnings by 6.0%, reporting an EPS of $1.09 versus an estimate of $1.03.
Revenue was up $5.59 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.15, leading to a 2.0% drop share price change the next day.
Here's a look at Enact Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.01</td>
<td>0.98</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.27</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>309.26M</td>
<td>298.83M</td>
<td>294.12M</td>
<td>299.81M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>309.59M</td>
<td>298.83M</td>
<td>291.58M</td>
<td>296.19M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enact Holdings <a href="https://www.benzinga.com/quote/ACT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Enact Holdings Q4 Earnings

The Q4 earnings report for Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) was released on Tuesday, February 4, 2025 at 04:15 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Enact Holdings beat estimated earnings by 6.0%, reporting an EPS of $1.09 versus an estimate of $1.03.
Revenue was up $5.59 million from the same period last year.
<h3>Previous Earnings Records</h3>
During the previous quarter, the company beat on EPS by $0.15, leading to a 2.0% drop share price change the next day.
Here's a look at Enact Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.01</td>
<td>0.98</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.27</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>309.26M</td>
<td>298.83M</td>
<td>294.12M</td>
<td>299.81M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>309.59M</td>
<td>298.83M</td>
<td>291.58M</td>
<td>296.19M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enact Holdings <a href="https://www.benzinga.com/quote/ACT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enact Holdings Q4 Earnings Assessment

The earnings results for Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) for Q4 were made public on Tuesday, February 4, 2025 at 04:15 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Enact Holdings beat estimated earnings by 6.0%, reporting an EPS of $1.09 versus an estimate of $1.03.
Revenue was up $5.59 million from the same period last year.
<h3>Overview of Past Earnings</h3>
In the previous quarter, the company beat on EPS by $0.15, resulting in a 2.0% drop change in the share price the following day.
Here's a look at Enact Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.01</td>
<td>0.98</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.27</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>309.26M</td>
<td>298.83M</td>
<td>294.12M</td>
<td>299.81M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>309.59M</td>
<td>298.83M</td>
<td>291.58M</td>
<td>296.19M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enact Holdings <a href="https://www.benzinga.com/quote/ACT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enact Holdings Earnings Review: Q4 Summary

Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) just disclosed its Q4 earnings on Tuesday, February 4, 2025 at 04:15 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Enact Holdings beat estimated earnings by 6.0%, reporting an EPS of $1.09 versus an estimate of $1.03.
Revenue was up $5.59 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company beat on EPS by $0.15 in the last quarter, resulting in a 2.0% drop share price change the following day.
Here's a look at Enact Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.01</td>
<td>0.98</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.27</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>309.26M</td>
<td>298.83M</td>
<td>294.12M</td>
<td>299.81M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>309.59M</td>
<td>298.83M</td>
<td>291.58M</td>
<td>296.19M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enact Holdings <a href="https://www.benzinga.com/quote/ACT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Enact Holdings Q4

Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 04:15 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Enact Holdings beat estimated earnings by 6.0%, reporting an EPS of $1.09 versus an estimate of $1.03.
Revenue was up $5.59 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.15, resulting in a 2.0% drop change in the share price the following day.
Here's a look at Enact Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.01</td>
<td>0.98</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.27</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>309.26M</td>
<td>298.83M</td>
<td>294.12M</td>
<td>299.81M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>309.59M</td>
<td>298.83M</td>
<td>291.58M</td>
<td>296.19M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enact Holdings <a href="https://www.benzinga.com/quote/ACT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enact Holdings: Q4 Earnings Insights

The earnings results for Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) for Q4 were made public on Tuesday, February 4, 2025 at 04:15 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Enact Holdings beat estimated earnings by 6.0%, reporting an EPS of $1.09 versus an estimate of $1.03.
Revenue was up $5.59 million from the same period last year.
<h3>Past Earnings Performance</h3>
During the previous quarter, the company beat on EPS by $0.15, leading to a 2.0% drop share price change the next day.
Here's a look at Enact Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.01</td>
<td>0.98</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.27</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>309.26M</td>
<td>298.83M</td>
<td>294.12M</td>
<td>299.81M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>309.59M</td>
<td>298.83M</td>
<td>291.58M</td>
<td>296.19M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enact Holdings <a href="https://www.benzinga.com/quote/ACT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enact Holdings Earnings Analysis: Q4 Recap

Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $1.03 by 5.83 percent. This is a 11.22 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $301.78 million which missed the analyst consensus estimate of $309.30 million by 2.43 percent. This is a 1.89 percent increase over sales of $296.19 million the same period last year.

Earnings Misses

Enact Holdings Q4 Adj $1.09 Beats $1.03 Estimate, Sales $301.78M Miss $309.30M Estimate

ALGT

AMGN

APAM

ARMK

ATEN

ATKR

AUDC

AVNW

AXTA

AZEK

AZPN

BALL

BERY

COLM

CRUS

CVRX

EGHT

ENPH

ENVA

FICO

FLNG

FOXA

GBDC

GOOG

GOOGL

HLNE

HUBB

ICHR

IESC

INGR

INMD

INNV

INTA

JKHY

JNPR

KLIC

KTCC

LANC

LARK

LUMN

MDLZ

MLAB

MPLX

MRCY

MSGS

MTCH

MUFG

OCSL

OSCR

PINC

PYPL

RACE

Earnings Scheduled For February 4, 2025

JP Morgan analyst Richard Shane maintains Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) with a Neutral and lowers the price target from $36 to $35.

JP Morgan Maintains Neutral on Enact Holdings, Lowers Price Target to $35

Management

Press Releases

Enact Announces Changes to its Board of Directors

Genworth Financial Announces Election of Steven Van Wyk to Board of Directors

Enact Releases 2024 Sustainability Report

Genworth Names Morris Taylor Chief Information Officer

Enact Holdings Set to Join S&P SmallCap 600

Genworth Financial Schedules Earnings Conference Call for May 1

Enact to Host First Quarter 2025 Earnings Call May 1st

Enact Announces 14% Increase to Quarterly Dividend and New $350 Million Share Repurchase Program

Comments

Enact Holdings

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO